Human Rotavirus Vaccine
Recommended · restricted VaccinesRestrictedFirst-line line
Prevention of rotavirus gastroenteritis (RVGE) in infants at 2 and 4 months of age.
2
Submissions
2 resub
2006–06
On the record
$15k–45k
ICER range
2 sourced ICERs · 2006
ICER stated
Cost basis
Access path
- Nov 2006Recommended · restricted
Comparator changed: placebo (standard medical management) → placebo (standard medical…
- Nov 2006Recommended · restricted
Comparator changed: placebo (standard medical management) → placebo (standard medical…
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
The resubmission estimated in the revised analysis that the incremental cost per QALY would be in the range $15,000 - $45,000. PSD · 2006
Cost-effectiveness accepted
Decision context
PopulationAll infants at 2 and 4 months of age for prevention of rotavirus gastroenteritis.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2006 | Recommended · restricted | placebo (standard medical management) | $15k–45k | RCT · Other |
| Nov 2006 | Recommended · restricted | placebo (standard medical management); also cost-minimisation comparison with RotaTeq | $15k–45k | RCT |
Similar precedents
Rotavirus Vaccine88%Rotavirus Vaccine, Live, Oral Liquid, Pentavalent86%Human Papillomavirus (Types 16 And 18) Recombinant, As04 Adjuvanted Vaccine69%Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine68%Hepatitis B Surface Antigen Recombinant Vaccine68%Trivalent Influenza Vaccine67%Zoster Virus Vaccine Live (Oka/Merk)67%Quadrivalent Influenza Vaccine (Split Virion, Inactivated)66%